Katharine Yen

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

  Blood · 2025-11-03

• AUTX-703, A Novel and Potent KAT2A and KAT2B Proteint Degrader, Induces Profound and Persistent Cell State Differentiation and Inhibits Growth in SCLC Model Systems

  Journal of Thoracic Oncology · 2025-08-01

• Abstract 350: AUTX-703, a novel and potent KAT2A and KAT2B protein degrader, induces differentiation and provides a potential therapeutic opportunity in subtypes of prostate cancer

  Cancer Research · 2025-04-21

• AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model

  Blood · 2024-11-05 · 2 citations

• 94 (PB082): AUTX-703, a novel and potent KAT2A and KAT2B protein degrader, induces profound cell state changes and inhibits growth in Small Cell Lung Cancer (SCLC) model systems

  European Journal of Cancer · 2024-10-01